The National Community Pharmacists Association (NCPA) and the American Association of Diabetes Educators (AADE) today announced a partnership that will expand counseling options for patients while offering community pharmacies a path to be compensated by Medicare and other insurers for diabetes management.

When metformin and a sulfonylurea or a glinide fail to bring Type 2 diabetes under control, adding pioglitazone may do the trick, French research suggests.

In patients with Type 1 diabetes and kidney disease, several serum markers of inflammation and endothelial dysfunction are associated with increasing prevalence and severity of diabetic retinopathy, investigators report.

Waist-to-hip circumference ratio (WHR) may be a better predictor of all-cause mortality in older adults versus body mass index (BMI), according to the results of a study.

Weight loss after bariatric surgery in mothers is associated with improvements in cardio-metabolic markers in their offspring that are sustained into adolescence, according to a published paper.

For patients with Type 2 diabetes, increased health care spending on risk factor control seems to be paying off, according to results of an economic analysis just released.

Arena Pharmaceuticals, Inc., said last Friday its obesity drug candidate Lorcaserin met primary efficacy and safety endpoints in the second late-stage trial, dubbed BLOSSOM (Behavioral modification and LOrcaserin Second Study for Obesity Management).

A solid majority of physicians favor creating a new public insurance option that would operate alongside existing private plans, according to a survey published online in The New England Journal of Medicine.

Women with diabetes are less likely to get important cancer screening tests than women without diabetes, new research confirms.

A new study shows that foreign-born adults with diabetes who move to the US are less apt to get certain types of recommended care than native-born US citizens with diabetes.